There are several studies investigating SGLT2 inhibitors in NAFLD that are actively recruiting (https://clinicaltrials.gov/ct2/home), although all are exclusively on patients with T2D. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.